Generics

The curious case of Wuhan’s Institute of Virology and remdesivir

Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

• Got a patent, now where to validate? 22-03-2021
• Second medical use: a regulatory perspective 08-02-2021
• Pricing, patents and the PMPRB in Canada 14-12-2020
• Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? 20-05-2020
• Medicinal cannabis: what next for Brazil? 21-10-2019

More generics features